NEW YORK – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed an agreement with REPROCELL Ltd., a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn’s disease patients. Fresh explants of ulcerative colitis and Crohn’s disease tissues obtained from surgical resection will be used as the test systems to investigate the therapeutic potential of the HT-003 drugs via measurement of key biomarkers for these diseases. All testing will be performed by REPROCELL Ltd..
“This collaboration expands Hoth’s efforts to characterize and develop therapies against inflammatory bowel diseases (“IBDs”), such as Crohn’s disease and ulcerative colitis,” stated Robb Knie, Chief Executive Officer of Hoth. “This is one of multiple studies being conducted on the anti-inflammatory properties of HT-003 and we expect these studies to allow us to accelerate finding solutions to unmet patient needs across multiple indications.”
The active pharmaceutical ingredient of HT-003 has demonstrated anti-inflammatory properties and targets the retinoic acid metabolism pathway. Recent data in published literature suggests that aberrant retinoic acid regulation may contribute to the underlying inflammatory mechanism that causes IBD symptoms and restoring retinoic acid homeostasis may provide a potential therapeutic benefit. IBDs represent a large health burden in the United States, affecting approximately 3 million adults age 18 years and older that continues to increase each year. IBDs are characterized by an inflammation-mediated disease pathology as a result of an excessive mucosal adaptive and innate immune response within the gastrointestinal tract.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth’s pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.
About REPROCELL:
REPROCELL is a contract research organization (CRO) that specializes in human tissue testing and iPSC research. They have worked with a range of clients, including 24 of the top 25 global Pharma companies, to better translate their discoveries into therapies. Areas of specialty include neurogenerative, bowel, skin, and respiratory diseases. REPROCELL is currently branching into the clinical space, with offerings in precision medicine and the generation of iPSCs for cell therapeutics. You can find out more at: https://www.reprocell.com/
Investor Contact:
LR Advisors LLC
Email: [email protected]
www.hoththerapeutics.com
Phone: (678) 570-6791